Patients with osteoporosis are at increased risk of fractures owing to the loss of bone strength, yet diagnosis and drug-treatment rates for this disease are relatively low. The low treatment rates are due, in part, to the asymptomatic nature of the disease, patients’ fears of osteoporosis drugs as being unsafe, and a widespread lack of appreciation for the seriousness of the disease. For drug-treated patients, bisphosphonates dominate first-line treatment, largely because of their widespread generic availability and strong physician familiarity. However, strong sales of select branded therapies continue to drive the therapy market. Here we explore prescribing patterns in osteoporosis and profile the patients who are drug-treated for osteoporosis.

Questions Answered

  • What is the patient share in osteoporosis for Prolia, Tymlos, Forteo, bisphosphonates, SERMs, and other key drug classes?
  • What are the demographic characteristics and clinical profiles of osteoporosis patients taking Prolia, Tymlos, Forteo, bisphosphonates, or other key drug classes?
  • What are the key risk factors, comorbidities, and coprescribed therapies by patient segment for osteoporosis?
  • How do patient cohorts for osteoporosis compare in care utilization and outcomes (physician visits and other healthcare encounters)?
  • What kind of insurance do osteoporosis patients have?
  • What are the reimbursed and out-of-pocket costs of osteoporosis treatment?

Product Description

Patient Profiler provides disease-specific, patient-level analysis of the key demographic, clinical, and cost-based metrics underlying brand use, all sourced from DRG’s comprehensive real-world data (RWD) repository.

Geographies covered: United States.

Key drugs covered: Prolia, Tymlos, Forteo, bisphosphonates, HRT, and SERMs.

Key analysis provided: Patient shares by brand and segment; patient demographics; clinical laboratory tests and values; risk factors and comorbidities; coprescribing and adjunctive therapy; prescribing for comorbid conditions; insurance type and reimbursement/cost analysis; utilization of care and physician and prescriber demographics.

Table of contents

  • Detailed, Expanded Analysis: Patient Profiler (US)
    • Osteoporosis - Patient Profiler - 2018

Author(s): David Rees, Ph.D

David Rees, , is a Business Insights Analyst with the Cardiovascular, Metabolic, and Renal Disorders team at Decision Resources Group. Prior to joining Decision Resources Group, Dr. Rees was a Postdoctoral Research Associate at Imperial College London, and the Institute of Cancer Research. For his doctoral research, he studied the structures of molecular machines in the Nobel Prize winning laboratory of Prof. Sir John Walker at the University of Cambridge. Dr. Rees earned his undergraduate from the University of Bath.


Related Reports

Osteoporosis | Current Treatment | US | 2016

The treatment of osteoporosis represents a large market that is dominated by the bisphosphonate drug class. Although more-efficacious therapies are available, step therapy is commonplace, with thes...

View Details

Osteoporosis | Current Treatment | Detailed, Expanded Analysis (US)

The treatment of osteoporosis represents a large market that is dominated by the bisphosphonate drug class. Although more-efficacious therapies are available, step therapy is commonplace, with th...

View Details

Osteoporosis | Current Treatment | Detailed, Expanded Analysis Treatment Algorithms Claims Data Analysis (US)

A wide array of drugs are available to treat osteoporosis. These drugs are generally effective in reducing patients’ risk of fracture and are well tolerated. Oral bisphosphonates, espe...

View Details

Osteoporosis | Landscape & Forecast | Disease Landscape & Forecast

Patients with osteoporosis are at increased risk of suffering fractures due to a loss in bone strength. These fractures, in turn, place a considerable burden on public health systems. The osteopo...

View Details